1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities

Hopes RIse As Diverse Contenders Enter Late-Stage Trials

 
• By Jung Won Shin

Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.

tunnel
Will There Be Light After A Long Tunnel? • Source: Shutterstock

With a few South Korean pharma firms now entering late-stage clinical trials for their Alzheimer's disease drug candidates, and many others actively pursuing development, hopes are brewing that the country will emerge as a challenger in the difficult space despite the high failure rates and ongoing controversies over Biogen, Inc.'s Aduhelm (aducanumab).

Smaller bioventures, rather than large pharma companies, appear to be more active at present, with several major firms including

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

 
• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By Jung Won Shin

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

More from Focus On Asia